Drug · Small Molecule

Pemetrexed

CI-DRUG-00000466Explore in graph →NCIt C61614 CHEMBL225072 CIViC Approved

Regulatory

Approvals (102)

Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.

emaRegulatory12 approval records · authority, jurisdiction and indication text as published.

Jurisdiction · authority	Cancer	Indication	Status	Approval date	Source
EU EMA	—	Malignant pleural mesotheliomaPemetrexed Baxter in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma. Non-small cell lung cancerPemetrexed Baxter in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see section 5.1). Pemetrexed Baxter is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy (see section 5.1). Pemetrexed Baxter is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see section 5.1).

Health Canada records are DIN-level: one row per marketed product (brand, strength, form). The Drug Product Database does not publish indications, so no cancer is stated for these rows, and a cancelled or dormant DIN is the status of that one product — not a withdrawal of the molecule.

Data updated 14 hours agoSource updated unknown

Derived

Development pipeline

Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.

Scope	Stage	Max phase	Active	Recruiting	Phase 3	Trials	Approvals	Jurisdictions	First approval	First trial
All cancers	Approved	Phase 4	238	117	200	827	102	CA, EU, US	Feb 4, 2004	1997-09
Malignant Lung Neoplasm	Approved	Phase 4	175	84	163	551	33	US	Feb 4, 2004	2001-08
Malignant Mesothelioma	Approved	Phase 4	9	4	6	45	7	US	Feb 4, 2004	1999-11
Malignant Bladder Neoplasm	Phase3	Phase 3	2	1	1	5	0

Curated evidence

Clinical evidence (16)

CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.

civicCuratedShowing 1–16 of 16 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
MTAP Deletion1
Pemetrexed	Bladder Urothelial Carcinoma

Clinical trials

Trials with this intervention (835)

Most recently updated first, 50 per page.

clinicaltrialsPublishedShowing 51–100 of 835 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT03715933	Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas	recruiting	Phase 1	411	Inhibrx Biosciences, IncINDUSTRY	6	Sep 8, 2026	clinicaltrials
NCT04092283	Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer

Molecule

Record

Kind: Small Molecule
Mechanism: Thymidylate synthase inhibitor; Dihydrofolate reductase inhibitor; GAR transformylase inhibitor
Targets: 3 genes
UNII: 9T47E4OM16
Aliases: ACT PEMETREXED, ALIMTA, Armisarte, AXTLE, Ciambra, L-Glutamic Acid, N-(4-(2-(2-Amino-4,7-dihydro-4-oxo-1H-pyrrolo(2,3-d)pyrimidin-5-yl)ethyl)benzoyl), LY-231514, LY231514, MTA, Multitargeted Antifolate, NSC-698037, Pemetrexed, Pemetrexed Accord, Pemetrexed Baxter, PEMETREXED DIPOTASSIUM, Pemetrexed Disodium, PEMETREXED DISODIUM, Pemetrexed Disodium Hemipentahydrate, Pemetrexed Fresenius Kabi, Pemetrexed Krka, Pemetrexed Lilly, Pemetrexed medac, Pemetrexed Pfizer, Pemetrexed Sandoz, Pemfexy, PEMFEXY, PEMRYDI RTU, TARO-PEMETREXED

Data updated 17 hours agoSource updated unknown

Identifiers

Codes (85)

Upstream identifiers kept as first-class codes; each links to its registry where a stable public URL exists.

System	Code	Label
ATC (WHO)	L01BA04	PEMETREXED
DIN (Health Canada)	02253437

CD274 Overexpression + MET Exon 14 Skipping MutationCD274 MET1
Carboplatin + PemetrexedCombination	Lung Adenocarcinoma	Predictive	C	Supports Sensitivity Response	3	submitted	EID11397 A 71-year old woman (non-smoker) was diagnosed with poorly differentiated lung adenocarcinoma following immunohistochemistry of tumor cells and biopsy staining. High PD-L1 expression was also confirme… (full text at CIViC) PMID 30600919 · Baba et al., 2019 · Open in CIViC	civic

CD274 Overexpression + MET Exon 14 Skipping MutationCD274 MET1

Carboplatin + PemetrexedCombination

Lung Adenocarcinoma

Predictive

Supports Sensitivity Response

submitted

EID11397

A 71-year old woman (non-smoker) was diagnosed with poorly differentiated lung adenocarcinoma following immunohistochemistry of tumor cells and biopsy staining. High PD-L1 expression was also confirme… (full text at CIViC)

PMID 30600919 · Baba et al., 2019 · Open in CIViC

EGFR Mutation2
Cisplatin + Pemetrexed + SintilimabCombination	Lung Carcinoma	Predictive	B	Supports Sensitivity Response	4	submitted	EID13098 In the randomized, double-blind phase III ORIENT-31 trial, patients with EGFR-mutated, nonsquamous non-small-cell lung cancer that had progressed following EGFR tyrosine kinase inhibitor therapy were … (full text at CIViC) PMID 37156249 · Lu et al., 2023 · Open in CIViC	civic
Gefitinib + PemetrexedCombination	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	B	Supports Sensitivity Response	3	submitted	EID7650 A phase 2 study was conducted to compare treatment with pemetrexed and gefinitib (P+G) versus gefinitib monotherapy for a population of 195 East Asian non-squamous NSCLC patients with EGFR mutations (… (full text at CIViC) PMID 31605797 · Yang et al., 2020 · Open in CIViC	civic

EGFR Exon 19 Deletion + EGFR L858R2
Amivantamab + Carboplatin + PemetrexedCombination	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	A	Supports Sensitivity Response	4	accepted	EID12156 In this phase III trial, 657 patients with locally advanced or metastatic NSCLC (Non-Small Cell Lung Cancer) harbouring EGFR mutations (exon 19 deletions or L858R) were treated with amivantamab plus c… (full text at CIViC) PMID 37879444 · Passaro et al., 2024 · Open in CIViC	civic
Carboplatin OR Cisplatin + Pembrolizumab + PemetrexedCombination	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	B	Supports Resistance	5	submitted	EID13097 In the randomized, double-blind phase III KEYNOTE-789 trial, 492 patients with EGFR exon 19 deletion- or L858R-positive, TKI-resistant metastatic nonsquamous non-small-cell lung cancer received pemetr… (full text at CIViC) PMID 39173098 · Yang et al., 2024 · Open in CIViC	civic